HEALTHCARE
Global Kidney Cancer Drugs Market - Industry Trends and Forecast to 2032
REPORT OVERVIEW
Global Kidney Cancer Drugs Market, By Cancer Type (Renal Cell Carcinoma (RCC), Papillary Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Transitional Cell Carcinoma, Wilms Tumor (Nephroblastoma), Renal Sarcoma, Angiomyolipoma, Oncocytoma, and Others), Drug Class (Monoclonal Antibodies, Trastuzumab, Pertuzumab, MTOR Inhibitors, Sirolimus, Everolimus, Temsirolimus, Immune Checkpoint Inhibitor, Atezolizumab, and Others), Drug Type (Branded, Generic), Route of Administration (Oral, Intravenous, Subcutaneous), End User (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Other therapies), Region (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2032.
Market Insights
The global kidney cancer drugs market size is valued to be USD xx million in 2023 and is expected to reach USD xx million by 2032, and it is expected to register a CAGR of xx% over the forecast period 2024-2032.
Kidney Cancer Drugs are pharmaceutical treatments used to treat kidney cancer, which is a type of cancer that begins in the kidney. These drugs fall into several categories, including chemotherapies, targeted treatments, and immunotherapies. Their goals are to either directly destroy cancer cells or to trigger the immune system to combat cancer. These drugs are intended to control kidney cancer, slow its progression, increase patient survival rates, and improve overall quality of life. The creation, manufacturing, and distribution of these pharmaceutical treatments make up the Kidney Cancer Drugs market. This market includes clinical trials, regulatory approvals, manufacturing, marketing, distribution, and research and development (R&D) of new pharmaceuticals.
The respective global report analyses market trends, consumer behaviour and industry dynamics to guide towards entry into new markets with ease. Also, it assists in tailoring market specific and related products and services to meet the needs, preferences, and expectations of target audience by delving into their psychology. The report also specializes with comprehensive and extensive competitive analysis which offers useful insights into competitor strengths, weaknesses, opportunities, and threats. The respective report offers exclusive insights into the potential impact of disruptive developments and technologies that are expected to completely transform corporate operations. The context includes tailor-made research solutions to create a stronger footprint in their particular industries thereby offering dedicated customized solutions according to the client needs which helps in addressing unique business challenges with more simplified and efficient decision-making solutions.
Market Dynamics
DRIVERS
- Increased Incidence of Kidney Diseases
- Rising awareness about cancer treatment
RESTRAINTS
- Side Effects of Kidney Cancer Drugs
- High Cost of Treatment
OPPORTUNITIES
- Higher Trend of Drug Approvals
- Increasing Healthcare Expenditure
CHALLENGES
- Regulatory challenges
- High failure rates in drug development
SEGMENTATION
- Cancer Type
- Renal Cell Carcinoma (RCC)
- Papillary Renal Cell Carcinoma
- Chromophobe Renal Cell Carcinoma
- Unclassified Renal Cell Carcinoma
- Transitional Cell Carcinoma
- Wilms Tumor (Nephroblastoma)
- Renal Sarcoma
- Angiomyolipoma
- Oncocytoma
- Others
- Drug Class
- Monoclonal Antibodies
- Trastuzumab
- Pertuzumab
- mTOR Inhibitors
- Sirolimus
- Everolimus
- Temsirolimus
- Immune Checkpoint Inhibitor
- Atezolizumab
- Avelumab
- Durvalumab
- Combined Therapies
- Interleukin-2
- Alpha-Interferon
- Others
- Drug Type
- Branded
- Generic
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
- Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- By Therapy
- Targeted Therapy
- Immunotherapy
- Chemotherapy
- Other therapies
The respective global report is completely customizable specific to regions (North America, Europe, Asia-Pacific, South America, Middle East and Africa), countries, and segments as per the client requirements.
REGIONAL SEGMENTATION
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- The Netherlands
- Belgium
- Turkey
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Singapore
- Malaysia
- Australia
- Thailand
- Philippines
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Chile
- Colombia
- Rest of South America
- Middle East and Africa
- Kingdom of Saudi Arabia
- South Africa
- U.A.E.
- Egypt
- Rest of Middle East and Africa
KEY MARKET PLAYERS
- Pfizer Inc.
- Novartis AG
- Bristol-Myers Squibb Company
- Roche Holding AG (Genentech, Inc.)
- Bayer AG
- Exelixis Inc.
- Merck & Co. Inc.
- Eisai Co. Ltd.
- Aveo Pharmaceuticals
- AstraZeneca PLC
Table OF CONTENTS
- SECTION 1 - INTRODUCTION
- 1.1 Taxonomy
- 1.2 Market Overview
- 1.3 Currency and Limitations
- 1.3.1 Currency
- 1.3.2 Limitations
- 1.4 Key Competitors
- SECTION 2 - RESEARCH METHODOLOGY
- 2.1 Research Approach
- 2.2 Data Collection and Validation
- 2.2.1 Secondary Research
- 2.2.2 Primary Research
- 2.3 Market Assessment
- 2.3.1 Market Size Estimation
- 2.3.2 Bottom-up Approach
- 2.3.3 Top-down Approach
- 2.3.4 Growth Forecast
- 2.4 Market Study Assumptions
- 2.5 Data Sources
- SECTION 3 - EXECUTIVE SUMMARY
- 3.1 Global Kidney Cancer Drugs Market, by Cancer Type
- 3.2 Global Kidney Cancer Drugs Market, by Drug Class
- 3.3 Global Kidney Cancer Drugs Market, by Drug Type
- 3.4 Global Kidney Cancer Drugs Market, by Route of Administration
- 3.5 Global Kidney Cancer Drugs Market, by End User
- 3.6 Global Kidney Cancer Drugs Market, by Distribution Channel
- 3.7 Global Kidney Cancer Drugs Market, by Therapy
- 3.8 Global Kidney Cancer Drugs Market, by Geography
- 3.9 Market Position Grid
- SECTION 4 - PREMIUM INSIGHTS
- 4.1 Regulatory Framework
- 4.1.1 Standards
- 4.1.2 Regulatory Landscape
- 4.2 Value Chain Analysis
- 4.3 Supply Chain Analysis
- 4.4 COVID-19 Impact
- 4.5 Russia-Ukraine War Impact
- 4.6 PORTER's Five Force Analysis
- 4.7 PESTLE Analysis
- 4.8 SWOT Analysis
- 4.9 Go to Market Strategy
- 4.10 Opportunity Orbit
- 4.11 Multivariate Modelling
- 4.12 Pricing Analysis
- SECTION 5 - MARKET DYNAMICS
- 5.1 Trends
- 5.1.1 Advancements in immunotherapy treatments
- 5.1.2 Increasing Healthcare Expenditure
- 5.1.3 Trend 3
- 5.2 Drivers
- 5.2.1 Increased Incidence of Kidney Diseases
- 5.2.2 Rising awareness about cancer treatment
- 5.2.3 Driver 3
- 5.2.4 Driver 4
- 5.3 Restraints
- 5.3.1 Side Effects of Kidney Cancer Drugs
- 5.3.2 High Cost of Treatment
- 5.3.3 Restraint 3
- 5.4 Opportunities
- 5.4.1 Higher Trend of Drug Approvals
- 5.4.2 Increasing Healthcare Expenditure
- 5.4.3 Opportunity 3
- 5.4.4 Opportunity 4
- 5.5 Challenges
- 5.5.1 Regulatory challenges
- 5.5.2 High failure rates in drug development
- 5.5.3 Challenge 3
- SECTION 6 - GLOBAL KIDNEY CANCER DRUGS MARKET, BY CANCER TYPE
- 6.1 Cancer Type Summary
- 6.2 Market Attractive Index
- 6.3 Global Kidney Cancer Drugs Market, by Cancer Type (2019-2032)
- SECTION 7 - GLOBAL KIDNEY CANCER DRUGS MARKET, BY DRUG CLASS
- 7.1 Drug Class Summary
- 7.2 Market Attractive Index
- 7.3 Global Kidney Cancer Drugs Market, by Drug Class (2019-2032)
- SECTION 8 - GLOBAL KIDNEY CANCER DRUGS MARKET, BY DRUG TYPE
- 8.1 Drug Type Summary
- 8.2 Market Attractive Index
- 8.3 Global Kidney Cancer Drugs Market, by Drug Type (2019-2032)
- SECTION 9 - GLOBAL KIDNEY CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION
- 9.1 Route of Administration Summary
- 9.2 Market Attractive Index
- 9.3 Global Kidney Cancer Drugs Market, by Route of Administration (2019-2032)
- SECTION 10 - GLOBAL KIDNEY CANCER DRUGS MARKET, BY END USER
- 10.1 End User Summary
- 10.2 Market Attractive Index
- 10.3 Global Kidney Cancer Drugs Market, by End User (2019-2032)
- SECTION 11 - GLOBAL KIDNEY CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL
- 11.1 Distribution Channel Summary
- 11.2 Market Attractive Index
- 11.3 Global Kidney Cancer Drugs Market, by Distribution Channel (2019-2032)
- SECTION 12 - GLOBAL KIDNEY CANCER DRUGS MARKET, BY THERAPY
- 12.1 By Therapy Summary
- 12.2 Market Attractive Index
- 12.3 Global Kidney Cancer Drugs Market, by By Therapy (2019-2032)
- SECTION 13 - GLOBAL KIDNEY CANCER DRUGS MARKET, BY GEOGRAPHY
- 13.1 Regional Summary
- 13.2 Market Attractive Index
- 13.3 Global Kidney Cancer Drugs Market, by Geography (2019-2032)
- SECTION 14 - NORTH AMERICA KIDNEY CANCER DRUGS MARKET
- 14.1 North America Summary
- 14.2 Market Attractive Index
- 14.3 North America Kidney Cancer Drugs Market, by Cancer Type (2019-2032)
- 14.4 North America Kidney Cancer Drugs Market, by Drug Class (2019-2032)
- 14.5 North America Kidney Cancer Drugs Market, by Drug Type (2019-2032)
- 14.6 North America Kidney Cancer Drugs Market, by Route of Administration (2019-2032)
- 14.7 North America Kidney Cancer Drugs Market, by End User (2019-2032)
- 14.8 North America Kidney Cancer Drugs Market, by Distribution Channel (2019-2032)
- 14.9 North America Kidney Cancer Drugs Market, by Therapy (2019-2032)
- 14.10 North America Kidney Cancer Drugs Market, by Country (2019-2032)
- 14.10.1 U.S.
- 14.10.2 Canada
- 14.10.3 Mexico
- 14.10.4 Rest of North America
- SECTION 15 - EUROPE KIDNEY CANCER DRUGS MARKET
- 15.1 Europe Summary
- 15.2 Market Attractive Index
- 15.3 Europe Kidney Cancer Drugs Market, by Cancer Type (2019-2032)
- 15.4 Europe Kidney Cancer Drugs Market, by Drug Class (2019-2032)
- 15.5 Europe Kidney Cancer Drugs Market, by Drug Type (2019-2032)
- 15.6 Europe Kidney Cancer Drugs Market, by Route of Administration (2019-2032)
- 15.7 Europe Kidney Cancer Drugs Market, by End User (2019-2032)
- 15.8 Europe Kidney Cancer Drugs Market, by Distribution Channel (2019-2032)
- 15.9 Europe Kidney Cancer Drugs Market, by Therapy (2019-2032)
- 15.10 Europe Kidney Cancer Drugs Market, by Country (2019-2032)
- 15.10.1 Germany
- 15.10.2 U.K.
- 15.10.3 France
- 15.10.4 Italy
- 15.10.5 Spain
- 15.10.6 Russia
- 15.10.7 The Netherlands
- 15.10.8 Belgium
- 15.10.9 Turkey
- 15.10.10 Rest of Europe
- SECTION 16 - ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET
- 16.1 Asia-Pacific Summary
- 16.2 Market Attractive Index
- 16.3 Asia-Pacific Kidney Cancer Drugs Market, by Cancer Type (2019-2032)
- 16.4 Asia-Pacific Kidney Cancer Drugs Market, by Drug Class (2019-2032)
- 16.5 Asia-Pacific Kidney Cancer Drugs Market, by Drug Type (2019-2032)
- 16.6 Asia-Pacific Kidney Cancer Drugs Market, by Route of Administration (2019-2032)
- 16.7 Asia-Pacific Kidney Cancer Drugs Market, by End User (2019-2032)
- 16.8 Asia-Pacific Kidney Cancer Drugs Market, by Distribution Channel (2019-2032)
- 16.9 Asia-Pacific Kidney Cancer Drugs Market, by Therapy (2019-2032)
- 16.10 Asia-Pacific Kidney Cancer Drugs Market, by Country (2019-2032)
- 16.10.1 China
- 16.10.2 India
- 16.10.3 Japan
- 16.10.4 South Korea
- 16.10.5 Singapore
- 16.10.6 Malaysia
- 16.10.7 Australia
- 16.10.8 Thailand
- 16.10.9 Philippines
- 16.10.10 Rest of Asia-Pacific
- SECTION 17 - SOUTH AMERICA KIDNEY CANCER DRUGS MARKET
- 17.1 South America Summary
- 17.2 Market Attractive Index
- 17.3 South America Kidney Cancer Drugs Market, by Cancer Type (2019-2032)
- 17.4 South America Kidney Cancer Drugs Market, by Drug Class (2019-2032)
- 17.5 South America Kidney Cancer Drugs Market, by Drug Type (2019-2032)
- 17.6 South America Kidney Cancer Drugs Market, by Route of Administration (2019-2032)
- 17.7 South America Kidney Cancer Drugs Market, by End User (2019-2032)
- 17.8 South America Kidney Cancer Drugs Market, by Distribution Channel (2019-2032)
- 17.9 South America Kidney Cancer Drugs Market, by Therapy (2019-2032)
- 17.10 South America Kidney Cancer Drugs Market, by Country (2019-2032)
- 17.10.1 Brazil
- 17.10.2 Argentina
- 17.10.3 Chile
- 17.10.4 Colombia
- 17.10.5 Rest of South America
- SECTION 18 - MIDDLE EAST AND AFRICA KIDNEY CANCER DRUGS MARKET
- 18.1 Middle East and Africa Summary
- 18.2 Market Attractive Index
- 18.3 Middle East and Africa Kidney Cancer Drugs Market, by Cancer Type (2019-2032)
- 18.4 Middle East and Africa Kidney Cancer Drugs Market, by Drug Class (2019-2032)
- 18.5 Middle East and Africa Kidney Cancer Drugs Market, by Drug Type (2019-2032)
- 18.6 Middle East and Africa Kidney Cancer Drugs Market, by Route of Administration (2019-2032)
- 18.7 Middle East and Africa Kidney Cancer Drugs Market, by End User (2019-2032)
- 18.8 Middle East and Africa Kidney Cancer Drugs Market, by Distribution Channel (2019-2032)
- 18.9 Middle East and Africa Kidney Cancer Drugs Market, by Therapy (2019-2032)
- 18.10 Middle East and Africa Kidney Cancer Drugs Market, by Country (2019-2032)
- 18.10.1 Kingdom of Saudi Arabia
- 18.10.2 South Africa
- 18.10.3 U.A.E.
- 18.10.4 Egypt
- 18.10.5 Rest of Middle East and Africa
- SECTION 19 - COMPANY SHARE ANALYSIS
- 19.1 Global Kidney Cancer Drugs Market, Company Share Analysis
- 19.2 North America Kidney Cancer Drugs Market, Company Share Analysis
- 19.3 Europe Kidney Cancer Drugs Market, Company Share Analysis
- 19.4 Asia-Pacific Kidney Cancer Drugs Market, Company Share Analysis
- SECTION 20 - COMPANY PROFILES
- 20.1 Pfizer Inc.
- 20.1.1 Company Snapshot
- 20.1.2 Financial Overview
- 20.1.3 Product Portfolio
- 20.1.4 Recent Developments
- 20.2 Novartis AG
- 20.2.1 Company Snapshot
- 20.2.2 Financial Overview
- 20.2.3 Product Portfolio
- 20.2.4 Recent Developments
- 20.3 Bristol-Myers Squibb Company
- 20.3.1 Company Snapshot
- 20.3.2 Financial Overview
- 20.3.3 Product Portfolio
- 20.3.4 Recent Developments
- 20.4 Roche Holding AG (Genentech, Inc.)
- 20.4.1 Company Snapshot
- 20.4.2 Financial Overview
- 20.4.3 Product Portfolio
- 20.4.4 Recent Developments
- 20.5 Bayer AG
- 20.5.1 Company Snapshot
- 20.5.2 Financial Overview
- 20.5.3 Product Portfolio
- 20.5.4 Recent Developments
- 20.6 Exelixis Inc.
- 20.6.1 Company Snapshot
- 20.6.2 Financial Overview
- 20.6.3 Product Portfolio
- 20.6.4 Recent Developments
- 20.7 Merck & Co. Inc.
- 20.7.1 Company Snapshot
- 20.7.2 Financial Overview
- 20.7.3 Product Portfolio
- 20.7.4 Recent Developments
- 20.8 Eisai Co. Ltd.
- 20.8.1 Company Snapshot
- 20.8.2 Financial Overview
- 20.8.3 Product Portfolio
- 20.8.4 Recent Developments
- 20.9 Aveo Pharmaceuticals
- 20.9.1 Company Snapshot
- 20.9.2 Financial Overview
- 20.9.3 Product Portfolio
- 20.9.4 Recent Developments
- 20.10 AstraZeneca PLC
- 20.10.1 Company Snapshot
- 20.10.2 Financial Overview
- 20.10.3 Product Portfolio
- 20.10.4 Recent Developments
- SECTION 21 - RELATED REPORTS
- SECTION 22 - DISCLAIMER
RESEARCH METHODOLOGY
The research methodology employed in Uniprism Market Research involves four basic steps namely research and data collection, data pre-processing, modeling and forecasting, quality assurance and output.
RESEARCH AND DATA COLLECTION
A tripod model research technique is followed for research and data collection in which various approaches such as primary research, secondary research, and product mapping are considered.
Primary research basically involves the process of conducting personalized interviews with market related professionals of major market players, investors, distributors, vendors and many more.
The secondary research include data published by government, annual reports, press releases, investor presentations of companies, white papers, certified publications, annual manufacturing limit of the respective industries related to the market, production consumption analysis of certain products respective to the market and many more.
Below mention are few of the sources which we have considered while estimating the market size:
For instance,
- Research articles published on Technium
- Science and MDPI
- Research publications by government approved associations and societies
Product mapping means the process of mapping the list of products that a key player contributes to the market as well as estimating the revenue of those products in order to define the Global Company share analysis of the respective Global Company in global, regional, and country level markets.
DATA PRE-PROCESSING
The term "data pre-processing" refers to the collection of procedures and methods used to clean, modify, and make ready for analysis the raw data gathered during research and data collection. The completion of this phase is necessary to guarantee that the data are reliable, consistent, and appropriate for statistical analysis and other data-driven tasks. The data pre-processing ensures that the information gathered from research and data collection is comparable and expressed in standard units, by the integration of missing data pointers and algorithmic approaches.
MODELING AND FORECASTING
The process of developing mathematical, statistical, or computational representations of real-world occurrences or relationships is known as modelling. These models are intended to replicate and explain market interactions, interdependence, and dynamics. These models are used by Uniprism Market Research to acquire a better knowledge of numerous market characteristics such as customer preferences, pricing elasticity, competition dynamics, and more. Depending on the individual study aims, many types of models are utilized, such as regression models, econometric models, decision tree models, and machine learning models.
Forecasting is the process of predicting future market conditions, trends, and occurrences using past data and models. Forecasting is used by Uniprism Market Research to estimate future sales, demand for products or services, market growth, and other important performance metrics. Forecasting accurately can assist organizations in making educated decisions about resource allocation, pricing, inventory management, and marketing tactics.
We create standardized bottom-up or top-down models that scale by leveraging data science and machine learning technology. All our market models consider the unique market characteristics of each country. Forecasting is based on major market indicators and a combination of traditional methodologies, such as exponential smoothing, time series analysis, regression analysis, and more modern techniques such as machine learning algorithms are all forecasting methodologies. The method chosen is determined on the nature of the data and the specific forecasting aims.
QUALITY ASSURANCE AND OUTPUT
Quality assurance and output involves the process of validation, adjustments, further publications of key market indicators. Extensive plausibility and consistency tests are performed on derived time series to ensure the high degree of quality of our market analysis. This quality assurance procedure also includes rigorous inspection, validation, and editing by an experienced management team to assure the dependability of the published data.